Skip to the page

Data / Drug companies / American Regent, Inc.

American Regent, Inc.: 72 products in the FDA NDC directory, labeler code 0517

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

American Regent, Inc. (labeler code 0517) lists 72 products in the FDA National Drug Code Directory, covering 37 finished drugs by generic name. By type: 72 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on August 19, 2025.

The request: Watch American Regent, Inc. (FDA labeler code 0517): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
0517
Products in commercial distribution
72
Packages
76
Finished drugs by generic name
37
Prescription products
72
Over the counter products
0
Flagged as original packager
69 of 69 products that carry the flag
Started marketing in the last 12 months
0
Products with a marketing end date set
1
Earliest marketing start
September 30, 1990
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)4461.1%
New drug applications (NDA)2230.6%
Other unapproved drugs68.3%

Products by type

TypeProductsShare
Prescription drugs72100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Injection, solution5677.8%
Injection56.9%
Inhalant45.6%
Injection, suspension34.2%
Injection, powder, lyophilized, for solution22.8%
Injection, powder, lyophilized, for suspension11.4%
Injection, solution, concentrate11.4%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Gvoke VialDx0517-2901Injection, solutionNew drug applications (NDA)August 19, 2025
Epinephrine0517-3030InjectionGeneric drugs (ANDA)October 9, 2024
Sodium Phosphates0517-7350Injection, solutionGeneric drugs (ANDA)June 21, 2024
Sodium Phosphates0517-7315Injection, solutionGeneric drugs (ANDA)June 21, 2024
Sodium Phosphates0517-7305Injection, solutionGeneric drugs (ANDA)June 21, 2024
Potassium Phosphates0517-2505Injection, solutionGeneric drugs (ANDA)October 13, 2023
Potassium Phosphates0517-2102Injection, solutionGeneric drugs (ANDA)October 13, 2023
Potassium Phosphates0517-2051Injection, solutionGeneric drugs (ANDA)October 13, 2023
Levocarnitine0517-1075Injection, solutionGeneric drugs (ANDA)June 21, 2023
Levocarnitine0517-1045Injection, solutionGeneric drugs (ANDA)June 21, 2023
Vasopressin0517-1030Injection, solutionNew drug applications (NDA)June 21, 2023
Paclitaxel protein bound particles albumin bound0517-4300Injection, powder, lyophilized, for suspensionNew drug applications (NDA)May 2, 2023
Epinephrine0517-1171Injection, solutionGeneric drugs (ANDA)January 31, 2023
Atropine Sulfate0517-1004Injection, solutionGeneric drugs (ANDA)August 2, 2022
Atropine Sulfate0517-1001Injection, solutionGeneric drugs (ANDA)August 2, 2022
Injectafer0517-0602Injection, solutionNew drug applications (NDA)June 1, 2022
Sterile Water0517-3020Injection, solutionOther unapproved drugsApril 22, 2022
Sterile Water0517-3010Injection, solutionOther unapproved drugsApril 22, 2022
Selenious Acid0517-6502Injection, solutionNew drug applications (NDA)March 28, 2022
Vasopressin0517-1020Injection, solutionNew drug applications (NDA)February 3, 2022
Multrys0517-9302Injection, solutionNew drug applications (NDA)September 1, 2021
Injectafer0517-0620Injection, solutionNew drug applications (NDA)June 1, 2021
Tralement0517-9305Injection, solutionNew drug applications (NDA)September 29, 2020
Fomepizole0517-0710Injection, solutionGeneric drugs (ANDA)July 31, 2020
Zinc Sulfate0517-6101Injection, solutionNew drug applications (NDA)May 18, 2020

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.